MacDougall Ann L. 4
4 · OPIANT PHARMACEUTICALS, INC. · Filed Mar 17, 2021
Insider Transaction Report
Form 4
MacDougall Ann L.
Director
Transactions
- Sale
Common Stock
2021-03-17$11.07/sh−6,606$73,128→ 20,838 total - Exercise/Conversion
Stock Option (right to buy)
2021-03-16$10.00/sh−2,231$22,310→ 7,620 totalExercise: $10.00Exp: 2021-05-16→ Common Stock (2,231 underlying) - Exercise/Conversion
Common Stock
2021-03-15$10.00/sh+6,483$64,830→ 25,483 total - Sale
Common Stock
2021-03-15$11.63/sh−5,600$65,128→ 19,883 total - Exercise/Conversion
Common Stock
2021-03-17$10.00/sh+7,279$72,790→ 27,444 total - Exercise/Conversion
Stock Option (right to buy)
2021-03-17$10.00/sh−7,279$72,790→ 341 totalExercise: $10.00Exp: 2021-05-16→ Common Stock (7,279 underlying) - Exercise/Conversion
Common Stock
2021-03-16$10.00/sh+2,231$22,310→ 22,114 total - Sale
Common Stock
2021-03-16$11.50/sh−1,949$22,414→ 20,165 total - Exercise/Conversion
Stock Option (right to buy)
2021-03-15$10.00/sh−6,483$64,830→ 9,851 totalExercise: $10.00Exp: 2021-05-16→ Common Stock (6,483 underlying)
Footnotes (6)
- [F1]The shares were sold to cover the $10 exercise price of the 6,483 vested stock options. The net shares of 883, after selling to cover the exercise price, will be held by the Reporting Person.
- [F2]This transaction was executed in multiple trades at prices ranging from $11.60 to $11.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]The shares were sold to cover the $10 exercise price of the 2,231 vested stock options. The net shares of 282, after selling to cover the exercise price, will be held by the Reporting Person.
- [F4]The shares were sold to cover the $10 exercise price of the 7,279 vested stock options. The net shares of 673, after selling to cover the exercise price, will be held by the Reporting Person.
- [F5]This transaction was executed in multiple trades at prices ranging from $11.00 to $11.30. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F6]On May 17, 2016, the reporting person was granted an option to purchase 35,000 shares of Common Stock. The options vest as follows: (i) 11,667 share upon the up listing of the Issuer to The NASDAQ Stock Market (which occurred on August 29, 2017); (ii) 11,667 shares upon the cumulative funding of the Issuer in excess of $5,000,000 by institutional investors, commencing May 5, 2016 (which performance criteria was met on December 13, 2016); and (iii) 11,666 shares upon the first submission of a New Drug Application ("NDA") to the FDA for one of Issuer's products by either the Issuer or an Issuer licensee.